RxDoctor Payments Data

Kenneth McGaffin, MD

Cardiovascular Disease · Monroeville, PANPI 1750481800

Payments from drug & device makers

$2,265in general payments, 2019–2025

Across 43 payments — averaging $52.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$600
  • Vifor (international) Ltd.$492
  • Vifor Pharma, Inc.$200
  • Scpharmaceuticals Inc.$129
  • Sanofi$125
  • E.r. Squibb & Sons, L.L.C.$106
  • plus $614 from 12 others

What the payments were for

  • Consulting fees$49222%
  • Speaking & faculty fees$1,02545%
  • Food & beverage$74833%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,265 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$200,570
Medicare patients
973
Services billed
2,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban438$459,802
XareltoRivaroxaban218$268,184
EntrestoSacubitril/Valsartan106$132,038
Repatha SureclickEvolocumab148$101,170
JardianceEmpagliflozin61$63,135
MultaqDronedarone Hcl25$40,079
BrilintaTicagrelor28$28,106
Droxidopa12$21,257
NexletolBempedoic Acid24$21,178
NexlizetBempedoic Acid/Ezetimibe17$17,552
FarxigaDapagliflozin Propanediol15$14,761
Dabigatran EtexilateDabigatran Etexilate Mesylate34$11,005
Repatha PushtronexEvolocumab12$6,930
Ezetimibe294$5,594
Metoprolol Succinate380$5,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$459,802438 claims
NovartisEntresto$86$132,038106 claims
Boehringer IngelheimJardiance$29$63,13561 claims
AstraZenecaBrilinta, Farxiga$16$42,86743 claims
Sanofi-aventis U.S. LLCMultaq$600$40,07925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →